Nuvalent Shares Are Trading Higher After the Company Highlighted Results for Its ROS1 and ALK-Positive NSCLC Programs and Accelerated Its Development Timeline. Also, the Company Announced a $350 Million Public Offering and Multiple Firms Raised Their...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.